An Open Label Study of L059 Intravenous (IV) in Japanese Epilepsy Subjects With Partial Onset Seizures

An Open-label, Multicenter Study to Evaluate the Safety of Adjunctive Treatment With Intravenous Levetiracetam (L059 IV) in Epilepsy Patients Aged ≥ 16 Years With Partial Onset Seizures

To evaluate the safety of Levetiracetam IV 15-minute infusion administered every 12 hours as adjunctive treatment in subjects with Partial Onset Seizures after switching from the equivalent Levetiracetam oral dose.

Inclusion Criteria:

• Subject is a male or female aged ≥ 16 years
• Subject has Partial Onset Seizures that are classifiable according to the 1981 International League Against Epilepsy (ILAE) classification of Epileptic Seizures
• Subject weighs ≥ 40 kg
• Subject is currently taking Levetiracetam (LEV) as an adjunctive antiepileptic oral treatment with 1 to 3 other Antiepileptic Drugs (AEDs)

Exclusion Criteria:

• Subject has problems with venous accessibility
• Subject has participated in another clinical/pharmacological study during the last 4 weeks prior to the Screening Visit
• Subject is pregnant or lactating
• Subject has a history of suicide attempt(s) or presents with current depressive signs, current suicidal ideation, and/or behavior
• Subject has clinically significant Electrocardiogram (ECG) abnormalities according to the investigator